Geoffrey Beran Rose - Mar 3, 2025 Form 4 Insider Report for Pulmonx Corp (LUNG)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ David Aaron Lehman, Attorney-in-Fact
Stock symbol
LUNG
Transactions as of
Mar 3, 2025
Transactions value $
-$41,193
Form type
4
Date filed
3/5/2025, 06:02 PM
Previous filing
Dec 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Sale -$3.7K -520 -0.18% $7.12 291K Mar 3, 2025 Direct F1
transaction LUNG Common Stock Sale -$6.51K -915 -0.31% $7.12 290K Mar 3, 2025 Direct F2
transaction LUNG Common Stock Sale -$16.6K -2.33K -0.8% $7.14 287K Mar 3, 2025 Direct F3
transaction LUNG Common Stock Sale -$14.4K -2.02K -0.7% $7.12 285K Mar 3, 2025 Direct F4
transaction LUNG Common Stock Award $0 +108K +37.86% $0.00 393K Mar 3, 2025 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on June 1, 2021.
F2 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2022.
F3 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
F4 These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
F5 Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 3, 2025.